The Global Amivantamab Market is projected to grow significantly, with one report suggesting a CAGR of 12.1% from 2026- 2033, reaching USD 3.5 billion by 2033, from USD 0.45 billion from 2026.
The Global Amivantamab Market refers to the worldwide commercial ecosystem surrounding Amivantamab, a targeted biologic therapy used primarily for treating non-small cell lung cancer (NSCLC) with specific EGFR exon insertion mutations. It encompasses drug development, manufacturing, regulatory approvals, distribution, and clinical adoption across healthcare systems. The market includes pharmaceutical companies, research institutions, and diagnostic providers involved in identifying eligible patients. The growth is driven by rising demand for precision oncology therapies, increasing cancer incidence, and ongoing clinical trials expanding therapeutic indications, positioning Amivantamab as a specialized yet rapidly evolving segment within oncology biologics markets globally.
The global Amivantamab market is shaped by strong trends toward precision medicine and combination therapies. Increasing adoption of targeted biologics that address genetic mutations, particularly EGFR and MET pathways, is transforming oncology treatment paradigms. Ongoing clinical trials exploring earlier-line use and combination regimens are expanding its therapeutic scope. Additionally, innovations such as subcutaneous formulations aim to improve patient convenience and adherence. Rising investments in biomarker testing and genomic profiling are further supporting uptake. The market is also benefiting from regulatory momentum following approvals in major regions, alongside growing interest in personalized cancer care and immunotherapy-based approaches.
Segmentation: The Global Amivantamab Market is segmented by Dosage Strength (0–100 µg, 100 µg–1 mg and Above 1 mg), Application (Pharmaceutics, Clinical Testing and Others), Indication (Non-Small Cell Lung Cancer (NSCLC), MET-Amplified NSCLC and Other Solid Tumors), Therapy Type (Monotherapy and Combination Therapy), Route of Administration (Intravenous and Subcutaneous), End User (Biopharmaceutical Companies, Hospitals, Cancer Treatment Centers, Specialty Clinics, Academic & Research Institutes and Contract Research Organizations (CROs)), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Direct Sales), Manufacturing Process (Recombinant Technology and Hybridoma Technology), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report provides the value (in USD million) for the above segments.
Market Drivers:
The major driver of the global Amivantamab market is the increasing prevalence of non-small cell lung cancer with specific genetic mutations such as EGFR exon 20 insertions. These mutations are often resistant to traditional therapies, creating a strong demand for targeted treatments. Amivantamab addresses this unmet need with a dual-action mechanism targeting EGFR and MET pathways, improving treatment efficacy. As cancer incidence continues to rise globally, particularly in aging populations and high-risk groups, the demand for advanced biologics is expanding. Improved awareness and diagnostic capabilities are further supporting identification of eligible patients, accelerating market growth.
Technological progress in precision medicine and biologics development is another key driver of the Amivantamab market. Advances in genomic sequencing and biomarker identification enable more accurate patient stratification, ensuring effective use of targeted therapies. The development of bispecific antibodies like Amivantamab represents a breakthrough in oncology innovation, offering enhanced efficacy compared to single-target treatments. Furthermore, increasing R&D investments and clinical trials exploring new indications and combination therapies are expanding its application. Regulatory support for innovative cancer treatments also accelerates approvals and adoption, reinforcing market growth and encouraging further innovation in targeted oncology therapeutics globally.
Market Restraints:
A key restraint in the global Amivantamab market is the relatively small eligible patient population. EGFR exon 20 insertion mutations occur in only about 1–2% of non-small cell lung cancer cases, significantly limiting the total addressable market. Additionally, effective use of the drug requires advanced genomic testing, which is not uniformly accessible across all healthcare systems, particularly in developing regions. This leads to underdiagnosis and reduced treatment adoption. High treatment costs and reimbursement challenges further constrain market penetration. As a result, despite strong clinical benefits, the market’s growth potential is inherently restricted by its niche therapeutic scope.
The Amivantamab market has notable socioeconomic implications by improving outcomes for patients with hard-to-treat lung cancer mutations. Enhanced survival rates and targeted treatment options reduce the burden on healthcare systems by minimizing ineffective therapies. However, high treatment costs and the need for advanced diagnostic testing create disparities in access, particularly in low- and middle-income regions. The market also drives economic activity through pharmaceutical innovation, clinical trials, and biotechnology investments. Additionally, improved patient quality of life contributes to productivity gains. Overall, while it advances precision oncology, equitable access and affordability remain key challenges influencing its broader socioeconomic impact.
Segmental Analysis:
The 100 µg–1 mg dosage segment is expected to witness the highest growth in the global Amivantamab market over the forecast period due to its optimal balance between efficacy and safety in clinical and therapeutic applications. This dosage range is widely used in translational research and dose-optimization studies, making it highly relevant for ongoing oncology trials. As precision medicine advances, demand for standardized intermediate dosing increases, particularly in early-phase and combination therapy trials. Pharmaceutical companies favor this range for its flexibility in scaling treatment regimens. Additionally, increasing regulatory approvals and clinical adoption further strengthen this segment’s growth trajectory across global healthcare systems and research environments.
The clinical testing segment is projected to experience the fastest growth in the global Amivantamab market, driven by a surge in ongoing and planned clinical trials. Researchers are actively exploring expanded indications beyond existing approvals, including earlier-line treatments and combination regimens. The growing emphasis on biomarker-driven therapies has increased the need for rigorous clinical validation, boosting demand for Amivantamab in testing environments. Additionally, collaborations between pharmaceutical firms and research institutions are accelerating trial activities globally. Regulatory support for innovative oncology drugs further fuels this segment. As precision oncology evolves, clinical testing remains central to validating safety, efficacy, and broader therapeutic applications, ensuring sustained growth.
The non-small cell lung cancer (NSCLC) segment is expected to witness the highest growth due to the increasing global burden of lung cancer and the significant unmet need in treating EGFR exon 20 insertion mutations. Amivantamab has demonstrated strong clinical efficacy in this niche patient population, making it a preferred targeted therapy. Rising adoption of genomic testing enables better identification of eligible patients, further driving demand. Additionally, expanding clinical trials investigating its use in earlier lines of NSCLC treatment are broadening its application. Improved awareness among oncologists and favorable regulatory approvals are also contributing to rapid growth in this segment across developed and emerging markets.
The combination therapy segment is anticipated to grow at the fastest rate in the Amivantamab market as researchers increasingly explore synergistic treatment approaches. Combining Amivantamab with chemotherapy, targeted agents, or immunotherapies has shown promising results in improving patient outcomes. This approach helps overcome resistance mechanisms commonly associated with monotherapies, enhancing overall treatment efficacy. Pharmaceutical companies are investing heavily in clinical trials evaluating combination regimens, which is accelerating segment growth. Furthermore, evolving treatment guidelines are gradually incorporating combination strategies for complex cancer cases. As oncology care shifts toward multi-modal treatment approaches, combination therapy is poised to become a key driver of innovation and market expansion.
The intravenous segment is expected to witness the highest growth in the Amivantamab market due to its established role as the primary route of administration for monoclonal antibody therapies. Intravenous delivery ensures precise dosing, rapid bioavailability, and effective systemic distribution, making it the preferred method in oncology settings. Hospitals and cancer treatment centers rely on this route for controlled administration under medical supervision. Additionally, existing clinical protocols and infrastructure strongly support intravenous use. While alternative delivery methods are emerging, intravenous administration remains dominant due to its proven efficacy and safety profile. Increasing patient volumes and expanding treatment indications continue to drive growth in this segment globally.
The biopharmaceutical companies segment is projected to register the highest growth due to increasing investments in targeted biologics and oncology research. These companies play a central role in drug development, clinical trials, and commercialization of Amivantamab. Growing competition in precision medicine is encouraging firms to expand their pipelines and explore new indications. Strategic collaborations, licensing agreements, and mergers are further strengthening their market position. Additionally, advancements in biotechnology and manufacturing capabilities enable efficient production of complex biologics. As demand for innovative cancer therapies rises, biopharmaceutical companies are scaling up R&D efforts, making this segment a key contributor to overall market expansion globally.
The retail pharmacies segment is expected to witness significant growth as access to specialty oncology drugs gradually expands beyond hospital settings. Increasing decentralization of healthcare services and improvements in cold-chain logistics are enabling retail pharmacies to handle complex biologics like Amivantamab. Patients increasingly prefer convenient access points for follow-up treatments and supportive medications, driving demand in this segment. Additionally, growing insurance coverage and reimbursement support are making such therapies more accessible through retail channels. Partnerships between pharmaceutical companies and pharmacy networks are also enhancing distribution reach. As healthcare systems evolve toward patient-centric models, retail pharmacies are emerging as an important distribution channel.
The recombinant technology segment is anticipated to witness the highest growth due to its critical role in the production of monoclonal antibodies like Amivantamab. This technology enables precise genetic engineering, ensuring high purity, consistency, and scalability in biologic manufacturing. Compared to traditional methods, recombinant approaches offer better efficiency and reduced risk of contamination. Increasing demand for high-quality biologics in oncology is driving adoption of advanced production technologies. Furthermore, continuous innovations in expression systems and bioprocessing techniques are enhancing yield and reducing costs. As pharmaceutical companies focus on large-scale production to meet growing demand, recombinant technology remains a cornerstone of market expansion.
The North American region is expected to witness the highest growth in the global Amivantamab market due to its advanced healthcare infrastructure and strong presence of leading biopharmaceutical companies. For instance, in Febraury 2026, The FDA approved a once-monthly subcutaneous regimen of amivantamab with hyaluronidase alongside lazertinib for first-line treatment of EGFR-mutated advanced non-small cell lung cancer. This advanced North America’s amivantamab market by improving patient convenience, increasing treatment adoption, strengthening market penetration, and supporting sustained demand growth across oncology care settings.
High adoption of precision medicine and widespread availability of genomic testing support early diagnosis and targeted treatment. Favorable regulatory frameworks and faster drug approvals further accelerate market penetration. Additionally, significant investments in oncology research and clinical trials contribute to regional dominance.
The rising prevalence of lung cancer and increasing awareness among healthcare professionals also drive demand. For instance, The American Cancer Society’s estimated for lung cancer in the US for 2026 are, about 229,410 new cases of lung cancer (110,910 in men and 118,500 in women) and about 124,990 deaths from lung cancer (63,040 in men and 61,950 in women). With robust reimbursement systems and continuous innovation, North America remains a key growth engine for the Amivantamab market.
The Amivantamab market is highly concentrated, dominated primarily by Johnson & Johnson through its subsidiary Janssen, which commercializes the drug. However, the broader competitive ecosystem includes biotechnology firms and research suppliers involved in antibody production and oncology innovation. Companies such as Thermo Fisher Scientific and ProteoGenix contribute to research and supply chains. The market is characterized by strategic collaborations, clinical development partnerships, and pipeline competition from alternative targeted therapies. Despite limited direct competitors for Amivantamab itself, the surrounding oncology biologics market remains highly competitive and innovation-driven.
The major players are:
Recent Development
Q1. What are the main growth-driving factors for this market?
The market is primarily driven by the rising incidence of EGFR-mutated non-small cell lung cancer (NSCLC) and the drug's breakthrough role in treating specific "exon 20 insertion" mutations. Key catalysts include expanded regulatory approvals for first-line combination therapies, the 2026 rollout of subcutaneous formulations that cut administration time from hours to minutes, and the global push toward biomarker-driven oncology.
Q2. What are the main restraining factors for this market?
Growth is hindered by the extremely high cost of specialized biologics, which limits accessibility in cost-sensitive healthcare systems. Significant barriers also include the biotechnological complexity of manufacturing bispecific antibodies, diagnostic gaps in comprehensive biomarker testing (required to identify eligible patients), and the relatively small addressable patient pool compared to broader, non-targeted cancer treatments.
Q3. Which segment is expected to witness high growth?
The Combination Therapy and First-line Treatment segments are witnessing the highest growth following new 2025-2026 approvals. By end-user, Specialized Cancer Centers are the fastest-expanding segment due to their advanced molecular diagnostic capabilities. Additionally, the MET-amplified NSCLC application is emerging as a high-growth area as clinical data supports wider usage beyond EGFR mutations.
Q4. Who are the top major players for this market?
The market is uniquely led by the innovator and a network of oncology and diagnostic partners: • Johnson & Johnson (Janssen Biotech) – Primary developer of Rybrevant (Amivantamab) • Roche (Genentech) • AstraZeneca • Pfizer Inc. • Amgen Inc. • Takeda Pharmaceutical Company • Merck & Co. • Yuhan Corporation (Partner for combination therapies like Lazertinib)
Q5. Which country is the largest player?
The United States is the largest player, holding approximately 42% of the global revenue share in 2026. This dominance is sustained by rapid clinical adoption, early FDA approvals, and a robust reimbursement landscape for precision medicine. However, the Asia-Pacific region (led by China and South Korea) is the fastest-growing market due to high lung cancer prevalence and expanding biotech investment.
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model